The present study was conducted to examine that impact of dietary xylanase (Xyl) and arabinofuranosidase (Abf) supplementation on the performance, protein and fat digestibility, the lipid peroxidation, the plasma biochemical traits, and the immune response of broilers. A total of 480, un-sexed, and one-day-old broilers (Ross 308) were randomly divided into three treatments with eight replicates, where chicks in the first treatment were fed basal diets and served as the control, chicks in the second treatment were fed diets formulated with reductions of 90 kcal/kg, and chicks in the third treatment were fed the same formulated diets used in the second group as well as the Xyl and Abf combination (Rovabio® Advance). Feed intake was decreased by the low energy diet, leading to an enhancement in feed efficiency enzyme supplementation in the low energy diet (p < 0.015). Both protein and fat digestibility were improved (p < 0.047) due to enzyme supplementation. Moreover, enzyme supplementation increased muscle total lipids content and decreased muscle thiobarbituric acid retroactive substance content. Furthermore, diets supplemented with Xyl and Abf exhibited an increase in antibody titers against the Newcastle disease virus (p < 0.026). In addition, enzyme supplementation increased gene expression related to growth and gene expression related to fatty acid synthesis. It could be concluded that dietary Xyl and Abf supplementation had beneficial impacts on growth, nutrient digestibility, lipid peroxidation, immune response, and gene expressions related to growth and fatty acid synthesis in broiler chickens fed low-energy diets.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.